Evidence map›Paper›PMID 33086064›Full record

ArticleCell reports2020

Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.

Yingwei Hu, Jianbo Pan, Punit Shah, Minghui Ao, Stefani N Thomas, Yang Liu, Lijun Chen, Michael Schnaubelt, David J Clark, Henry Rodriguez and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 152 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Panorama: a database for the oncogenic evaluation of somatic mutations in pan-cancer.Database : the journal of biological databases and curation · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Matrix Metalloproteinases as Candidate Antigenic Determinants for Anti-Tumor Autoantibodies in Human Ovarian Cancer: A Post Hoc Analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  19. Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Yingwei HuDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Jianbo PanDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Punit ShahDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Minghui AoDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Stefani N ThomasDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Yang LiuDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Lijun ChenDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Michael SchnaubeltDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
David J ClarkDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Henry RodriguezOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA.
Emily S BojaOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA.
Tara HiltkeOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA.
Christopher R KinsingerOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA.
Karin D RodlandBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352, USA.
Qing Kay LiDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Jiang QianDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Zhen ZhangDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Daniel W ChanDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA. Electronic address: dchan@jhmi.edu.
Hui ZhangDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA. Electronic address: huizhang@jhu.edu.
Clinical Proteomic Tumor Analysis Consortium
Johns Hopkins University · USNational Cancer Institute · USPacific Northwest National Laboratory · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3M
PNNL Proteome Characterization CenterU24CA210955 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI LIU, TAO, SMITH, RICHARD D · 2016 to 2020
$5.3M
NCI NIH HHS P30 CA006973NCI NIH HHS U24 CA160036NCI NIH HHS U24 CA210955NCI NIH HHS U24 CA210985
6 · The paper itself

Abstract

Many gene products exhibit great structural heterogeneity because of an array of modifications. These modifications are not directly encoded in the genomic template but often affect the functionality of proteins. Protein glycosylation plays a vital role in proper protein functions. However, the analysis of glycoproteins has been challenging compared with other protein modifications, such as phosphorylation. Here, we perform an integrated proteomic and glycoproteomic analysis of 83 prospectively collected high-grade serous ovarian carcinoma (HGSC) and 23 non-tumor tissues. Integration of the expression data from global proteomics and glycoproteomics reveals tumor-specific glycosylation, uncovers different glycosylation associated with three tumor clusters, and identifies glycosylation enzymes that were correlated with the altered glycosylation. In addition to providing a valuable resource, these results provide insights into the potential roles of glycosylation in the pathogenesis of HGSC, with the possibility of distinguishing pathological outcomes of ovarian tumors from non-tumors, as well as classifying tumor clusters.

Indexed as

Biomarkers, TumorCystadenocarcinoma, SerousFemaleGlycoproteinsGlycosylationHumansOvarian NeoplasmsProteomicsTissue BanksBiomarkers, TumorGlycoproteinsCPTACglycoproteomicsglycosylationHGSChigh-grade serous ovarian carcinomamass spectrometryproteomicstumor clusters

Identifiers

PMID33086064
PMCPMC7970828
OpenAlexW3093532012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.